Search for drugs:
Typing the drug name to query
LEVOMILNACIPRAN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dose 2.5 times the maximum recommended dose, levomilnacipran does not prolong QTc to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
3
24089
Other ADRs
1763
38379824
Odds Ratio = 2.712
Drug Property Information
ATC Code(s):
Active Ingredient:LEVOMILNACIPRAN HYDROCHLORIDE
Active Ingredient UNII:371U2ZK31U
Drugbank ID:DB08918
PubChem Compound:6917779
CTD ID:D000078862
CAS Number:96847-54-0
Dosage Form(s):capsule, extended release
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1
Reference
1: Levomilnacipran for the treatment of major depressive disorder: a review.
[Asnis Gregory M,Henderson Margaret A]Neuropsychiatr Dis Treat,2015 Jan 9;11:125-35. PMID: 25657584
2: Risk of QT/QTc prolongation among newer non-SSRI antidepressants.
[Jasiak Natalia M,Bostwick Jolene R]Ann Pharmacother,2014 Dec;48(12):1620-8. PMID: 25204465
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.